Improving clinical outcomes for patients with cancer-associated thrombosis

Thromb Haemost 2008; 100(03): 367-368
DOI: 10.1160/TH08-08-0517

Editorial Focus

Schattauer GmbH

Ajay Kakkar

¹Barts and The London School of Medicine and Dentistry and Thrombosis Research Institute, London, UK

References
1 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
2 Levine MN. Can we optimise treatment of thrombosis?. Cancer Treat Rev 2003; 29 (Suppl. 02) 19-22.
3 Lyman GH, Khorana AA, Falanga A. et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
4 Trujillo-Santos J, Nieto JA, Antonio J. et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 435-439.
5 Khorana A, Kuderer MN, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
6 Zwicker JL. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008; 34: 195-198.